Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;53(3):263-270.
doi: 10.1016/j.dld.2020.12.013. Epub 2020 Dec 26.

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population

Affiliations
Observational Study

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population

Giovanni Maconi et al. Dig Liver Dis. 2021 Mar.

Abstract

Background: It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19.

Objectives: This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders.

Methods: This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed.

Results: 1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17).

Conclusion: IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.

Keywords: COVID-19; Inflammatory bowel disease; Symptoms.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors have indicated they have no potential conflicts of interest relevant to this article to disclose.

Comment in

References

    1. Ashour H.M., Elkhatib W.F., Rahman M.M., Elshabrawy H.A. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020;9(3) - PMC - PubMed
    1. Han Q., Lin Q., Jin S., You L. Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect. 2020 pii: S0163-4453(20)30087-6.
    1. Guan W.-.J., Ni Z.-.Y., Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
    1. Odone A., Delmonte D., Scognamiglio T. COVID-19 deaths in Lombardy, Italy: data in context. The Lancet Public Health. 2020:1. –1. - PMC - PubMed
    1. WHO - Coronavirus disease (COVID-19) advice for the public Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-f....

Publication types